Clinical Trial

Imaging Immune Activation in HIV by PET-MR

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 24, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-09-24; most recent amendment 2024-10-22.
Trial Details
NCT Number NCT03684655
Lead Sponsor CellSight Technologies, Inc.
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
Conditions HIV Infections
Enrollment 30 participants
Start Date 2018-09-21
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-11-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-24